For: | Yang SZ, Wang AQ, Du J, Wang JT, Yu WW, Liu Q, Wu YF, Chen SG. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma. World J Gastroenterol 2016; 22(25): 5814-5821 [PMID: 27433094 DOI: 10.3748/wjg.v22.i25.5814] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i25/5814.htm |
Number | Citing Articles |
1 |
Achira Namjan, Anchalee Techasen, Watcharin Loilome, Prakasit Sa-ngaimwibool, Apinya Jusakul. ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ 2020; 8: e10464 doi: 10.7717/peerj.10464
|
2 |
Yong-Na Wu, Li-Hong He, Zhong-Tian Bai, Xun Li. <p>NRP1 is a Prognostic Factor and Promotes the Growth and Migration of Cells in Intrahepatic Cholangiocarcinoma</p>. Cancer Management and Research 2020; : 7021 doi: 10.2147/CMAR.S260091
|
3 |
Feiling Feng, Xiaobing Wu, Xiaoliang Shi, Qingxiang Gao, Yue Wu, Yong Yu, Qingbao Cheng, Bin Li, Bin Yi, Chen Liu, Qing Hao, Lin Zhang, Chunfang Gao, Xiaoqing Jiang. Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients. International Journal of Clinical Oncology 2021; 26(4): 717 doi: 10.1007/s10147-020-01846-z
|
4 |
Huibin Yang, Junyu Huo, Xin Li. Identification and validation of a five-gene prognostic signature for hepatocellular carcinoma. World Journal of Surgical Oncology 2021; 19(1) doi: 10.1186/s12957-021-02202-9
|
5 |
Ruihua Wang, Mei Chen, Xiaojun Ye, Karen Poon. Role and potential clinical utility of ARID1A in gastrointestinal malignancy. Mutation Research/Reviews in Mutation Research 2021; 787: 108360 doi: 10.1016/j.mrrev.2020.108360
|
6 |
Jun-Jie Liu, Mi Zhou, Tong Yuan, Zhi-Yong Huang, Zun-Yi Zhang. Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges. World Journal of Gastroenterology 2025; 31(15): 104901 doi: 10.3748/wjg.v31.i15.104901
|
7 |
Michele Simbolo, Caterina Vicentini, Andrea Ruzzenente, Matteo Brunelli, Simone Conci, Matteo Fassan, Andrea Mafficini, Borislav Rusev, Vincenzo Corbo, Paola Capelli, Emilio Bria, Serena Pedron, Giona Turri, Rita T. Lawlor, Giampaolo Tortora, Claudio Bassi, Alfredo Guglielmi, Aldo Scarpa. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-25669-1
|
8 |
Veronica Porreca, Cristina Barbagallo, Eleonora Corbella, Marco Peres, Michele Stella, Giuseppina Mignogna, Bruno Maras, Marco Ragusa, Carmine Mancone. Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches. Cancers 2024; 16(16): 2889 doi: 10.3390/cancers16162889
|
9 |
Han Wang, Weiren Liu, Mengxin Tian, Zheng Tang, Xifei Jiang, Peiyun Zhou, Zhenbin Ding, Yuanfei Peng, Zhi Dai, Shuangjian Qiu, Jian Zhou, Jia Fan, Yinghong Shi. Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. BioScience Trends 2017; 11(4): 469 doi: 10.5582/bst.2017.01080
|
10 |
Dan Høgdall, Ole F. Larsen, Dorte Linnemann, Tim Svenstrup Poulsen, Estrid V. Høgdall. Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. APMIS 2020; 128(1): 3 doi: 10.1111/apm.13003
|
11 |
Yi Shi, Jianfeng Bai, Shuwei Guo, Jiandong Wang. Wntless Is Highly Expressed in Advanced-Stage Intrahepatic Cholangiocarcinoma. The Tohoku Journal of Experimental Medicine 2018; 244(3): 195 doi: 10.1620/tjem.244.195
|
12 |
Chao Bi, Mei Liu, Weiqi Rong, Fan Wu, Yang Zhang, Shengtao Lin, Yunhe Liu, Jianxiong Wu, Liming Wang. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-5429-3
|
13 |
Wellington Andraus, Francisco Tustumi, José Donizeti de Meira Junior, Rafael Soares Nunes Pinheiro, Daniel Reis Waisberg, Liliana Ducatti Lopes, Rubens Macedo Arantes, Vinicius Rocha Santos, Rodrigo Bronze de Martino, Luiz Augusto Carneiro D’Albuquerque. Molecular Profile of Intrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences 2023; 25(1): 461 doi: 10.3390/ijms25010461
|
14 |
Ning Xu, Lili Wang, Ping Sun, Suyang Xu, Shiping Fu, Zhihua Sun. Low Arid1a Expression Correlates with Poor Prognosis and Promotes Cell Proliferation and Metastasis in Osteosarcoma. Pathology & Oncology Research 2019; 25(3): 875 doi: 10.1007/s12253-017-0338-8
|
15 |
Tetiana Glushko, James Costello, Ranjit Chima, Melissa McGettigan, Richard Kim, Daniel Jeong, Aliya Qayyum. Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection. European Journal of Radiology 2025; 187: 112056 doi: 10.1016/j.ejrad.2025.112056
|
16 |
Charupong Saengboonmee, Kanlayanee Sawanyawisuth, Yaovalux Chamgramol, Sopit Wongkham. Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Review of Anticancer Therapy 2018; 18(6): 579 doi: 10.1080/14737140.2018.1467760
|
17 |
Jiao Wang, Fujing Ge, Tao Yuan, Meijia Qian, Fangjie Yan, Bo Yang, Qiaojun He, Hong Zhu. The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma. Expert Opinion on Therapeutic Targets 2022; 26(9): 781 doi: 10.1080/14728222.2022.2137020
|
18 |
Shankun Zhao, Youwen Xu, Weizhou Wu, Pan Wang, Yichao Wang, Hao Jiang, Jie Zhu. ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.693295
|